The Glucagon Emergency Kit is an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes.
This kit includes Glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of Sterile Water for Injection, USP.
The Glucagon Emergency Kit is designed to be convenient and easy to use. Patients can carry it with them, so it is available should they experience severe hypoglycemia.
The bright orange case makes it easy for a patient or caregiver to find it and act quickly. To help make the Glucagon Emergency Kit more affordable, there is a co-pay assistance programme for patients who qualify.
Fresenius Kabi is also making injection training kits available to health care providers to help educate patients.
Glucagon for Injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients.
The company's US headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion